Johnson & Jonson

Showing 2 posts of 2 posts found.


Amgen biosimilar proves non-inferior to J&J’s Remicade in rheumatoid arthritis

June 27, 2018
Research and Development, Sales and Marketing Amgen, Johnson & Jonson, Remicade, pharma, rheumatoid arthritis

Amgen has unveiled new Phase 3 data for its biosimilar version of Johnson & Johnson’s Remicade (infliximab), confirming that it …

Tylenol recall warrants thorough, public investigation, says ISMP

November 15, 2010
Manufacturing and Production FDA, ISMP, Institute for Safe Medication Practices, Johnson & Jonson, MedWatch, Tylenol, Tylenol recall

Johnson & Jonson’s recall of Tylenol painkiller products was one of the key safety trends identified in the last quarter …

Latest content